{
    "organizations": [],
    "uuid": "b2b248eec39b0a92688b77d51ea74e60f4637ca5",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-genentechs-announces-results-from/brief-genentechs-announces-results-from-phase-iii-haven-3-study-evaluating-hemlibra-prophylaxis-idUSFWN1SS00F",
    "ord_in_thread": 0,
    "title": "BRIEF-Genentech's Announces results from Phase III Haven 3 study evaluating Hemlibra prophylaxis",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 21 (Reuters) -\n* GENENTECHâ€™S HEMLIBRA (EMICIZUMAB-KXWH) REDUCED TREATED BLEEDS BY 96 PERCENT COMPARED TO NO PROPHYLAXIS IN PHASE III HAVEN 3 STUDY IN HEMOPHILIA A WITHOUT FACTOR VIII INHIBITORS\n* GENENTECH - HEMLIBRA REDUCED TREATED BLEEDS BY 96 PERCENT COMPARED TO NO PROPHYLAXIS IN PHASE III HAVEN 3 STUDY IN HEMOPHILIA A WITHOUT FACTOR VIII INHIBITORS\n* GENENTECH- DATA FROM BOTH HAVEN 3 AND HAVEN 4 STUDIES ARE BEING SUBMITTED TO HEALTH AUTHORITIES AROUND WORLD FOR APPROVAL CONSIDERATION Source text for Eikon: Further company coverage:\n ",
    "published": "2018-05-21T14:07:00.000+03:00",
    "crawled": "2018-05-22T19:32:27.009+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "genentech",
        "hemlibra",
        "reduced",
        "treated",
        "bleeds",
        "percent",
        "compared",
        "prophylaxis",
        "phase",
        "iii",
        "study",
        "hemophilia",
        "without",
        "factor",
        "viii",
        "inhibitor",
        "genentech",
        "hemlibra",
        "reduced",
        "treated",
        "bleeds",
        "percent",
        "compared",
        "prophylaxis",
        "phase",
        "iii",
        "study",
        "hemophilia",
        "without",
        "factor",
        "viii",
        "inhibitor",
        "data",
        "study",
        "submitted",
        "health",
        "authority",
        "around",
        "world",
        "approval",
        "consideration",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}